2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2024 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
John V. Heymach, MD, PhD, chairman, Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses the significance of nivolumab (Opdivo) for patients with lung cancer.
John V. Heymach, MD, PhD, chairman, Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses the significance of nivolumab (Opdivo) for patients with lung cancer.
The long-term follow-up for nivolumab is important for the field, states Heymach. Overall, patients in the CheckMate-026 trial saw an improvement in survival of a few months.
The long-term data informs researchers that there are some patients that are still benefitting from the treatment years later, explains Heymach.
Related Content: